The race is over … another American vaccine by the end of November

It looks like the global vaccine race has quickly returned to work in an attempt to find a solution that ends the human crisis that has been ongoing since the new Corona virus emerged months ago, affecting more than a million people. .

After the American company “Pfizer” and the German “Biontech” announced that the vaccine against Covid-19 they are developing was 90% effective after the initial analysis of the results of the third phase of clinical trials, the company Pharmaceuticals Novavax announced today that its Corona vaccine has gained approval. Prompted by the US Food and Drug Administration.

The company added that its vaccine will be accelerated with help from the U.S. government agency with the aim of developing it to be effective and safe against the pandemic.

With end of November

Officials also expected the company to complete its drug, called NVXCoV2373, in phase three trials in the United States and Mexico by the end of November.

Novavax announced its commitment to a data-driven and scientifically rigorous approach to demonstrate safety and efficacy while accelerating regulatory review of this clinical program.

90% efficient

It should be noted that the American company “Pfizer” and German “Biontech” announced on Monday that the vaccine against Covid-19 that they are developing is 90% effective after the preliminary analysis of the results of the third phase of clinical trials , which is the last one before submitting its license application.

British authorities have revealed that the vaccine could be ready locally at the end of next December.

The two companies explained that protection against the coronavirus is achieved at a high rate after 28 days of taking the first dose, and is not completed until a week after the second dose.

And they said in a joint statement that “this vaccine effectiveness” was measured by comparing the number of participants infected with the corona virus emerging in the group that received the vaccine and the number of people infected from another group that received. a placebo vaccine, “seven days after receiving the second dose” and 28 days after receiving the dose. First.

Further, Dr Albert Burla, Chairman and CEO of Pfizer, said: “Today is a great day for science and humanity. The first set of results from the third phase of the Covid vaccine trial -19 provides preliminary evidence of our vaccine’s ability to prevent corona, adding: “We have reached this landmark achievement in our vaccine development program at a time that the world needs most, with high rates of infection. record. “

It is noteworthy that the new Corona virus, which destroyed stone and people, has infected more than 50 million people worldwide since it emerged in China about 11 months ago and caused heavy losses to the economy global.